T ranscatheter aortic valve replacement (TAVR) is an established treatment for patients with severe symptomatic aortic stenosis at intermediate to high operative risk. 1 Although clinical outcomes continue to improve following TAVR through device iterations and refinement of procedural technique, accurate patient risk stratification remains challenging.
Myocardial infarction associated with percutaneous coronary intervention (type 4a) and coronary artery bypass surgery (type 5) is associated with worse clinical outcomes. 2, 3 The Valve Academic Research Consortium (VARC) has developed criteria for the definition of myocardial infarction in the context of TAVR, which includes a combination of biomarker elevation and clinical evidence of ischemic insult. 4 Factors affecting this include patient-specific characteristics, such as left ventricular and renal impairment, or procedural events, such as mechanical trauma, hypotension, and calcific embolization. Observational studies evaluating the prognostic impact of myocardial infarction during TAVR have often studied biomarker elevation alone because of inaccessibility of data on the associated clinical evidence of ischemic insult. The studied variable, more specifically periprocedural myocardial injury (PPMI), is shown to occur in up to 59% of patients 5 undergoing TAVR. However, these studies have yielded discrepant results with some demonstrating that PPMI predicts mortality, [5] [6] [7] [8] [9] with other studies finding no clear association between PPMI and outcome. [10] [11] [12] As ongoing efforts are directed at improving procedural results, there has been interest in establishing the strength of the link between PPMI and outcomes, as the occurrence of PPMI could act as a surrogate marker for refining procedural technique. 13, 14 We, therefore, performed a systematic review and meta-analysis to assess whether PPMI was associated with short-and long-term outcomes in patients undergoing TAVR.
METHODS

Data Sources and Search Strategy
The data, analytic methods, and study materials will be made available to other researchers for purposes of reproducing the results or replicating the procedure. This material can be obtained by contacting the corresponding author.
Electronic searches of the MEDLINE, EMBASE, and PubMed databases were performed to identify studies reporting the occurrence of PPMI and clinical outcomes following TAVR until June 21, 2018. Searches were performed using a combination of keywords and MeSH terms for TAVR, PPMI, troponin, and creatine kinase-MB (CK-MB). An example search strategy is presented in Table I in the Data Supplement. Searches were not limited by language. The references of eligible articles were reviewed, along with manual searches of presentations and abstracts from major international conferences. The study protocol was prospectively registered with the PROSPERO international register (registration number CRD42018096603) and fully adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement.
Study Selection
Studies were considered for inclusion if they met the following criteria: (1) patients who had undergone TAVR, (2) cardiac-specific biomarker elevation within 72 hours, (3) reported mortality at 30 days or 1 year grouped by biomarker status, (4) standardized or similarly comparable definitions for PPMI, and (5) fully published status. The definitions for PPMI were identified for each of the studies by the type of biomarker assay used and the biomarker elevation thresholds set by study investigators. Only cardiac-specific biomarkers were used. Studies were included if they used they used standardized thresholds which were agreed as those set in VARC or the superseding VARC-2 criteria, 4 that is, peak troponin or CK-MB >5× upper reference limit (URL) in the original VARC criteria, or troponin >15× or CK-MB >5× URL in VARC-2 criteria. Other studies were considered if they were deemed clinically comparable. Seven of the 9 studies used these standardized criteria 5, [7] [8] [9] [10] [11] [12] with one study 15 defining PPMI by a troponin threshold of 166 pg/mL (12× URL) and a second using a CK-MB threshold of >2× URL. 6 The study-specific definitions of PPMI for each study are presented in Table II in the Data Supplement.
Data Items and Collection Process
Data items to be collected were prespecified before conducting the literature search. Three investigators (Dr Michail, J.N. Cameron, and Dr Montone) independently conducted the literature search and performed data extraction. Four articles required data extraction of 30-day and 1-year all-cause mortality from survival curves 5,9,12,15 using the methodology as set
WHAT IS KNOWN
• Periprocedural myocardial injury can identify patients at highest risk for subsequent adverse clinical events in those undergoing percutaneous coronary intervention or cardiac surgery.
• Studies investigating its relevance in patients undergoing transcatheter aortic valve replacement have yielded discrepant results and so its value in this cohort remains unknown.
WHAT THE STUDY ADDS
• Our study confirms that the occurrence of periprocedural myocardial injury in patients undergoing transcatheter aortic valve replacement is common and associated with an increased risk of both 30-day and 1-year all-cause death.
• Our data also demonstrate that periprocedural myocardial injury identifies the patients at increased risk of postprocedural neurological events and those that have a greater necessity for permanent pacemaker implantation.
out by Parmar et al. 16 Deaths in control and exposure groups were estimated across nonoverlapping time intervals assuming a uniform censoring over time. Weighted summation of each time interval's natural log hazard ratio, with weighting inversely proportional to their variance, allowed for overall 30-day and 1-year natural log hazard ratios to be back calculated from the curves. Standard errors were measured using the log-rank test. Corresponding hazard ratios and their CIs were calculated using the above values and compared with those quoted in the text to assess accuracy. Further, the χ 2 test of the null hypothesis was used to ensure the range of the P value calculated using the log-rank test was in keeping with the survival curve P value if quoted. Finally, 30-day and 1-year mortality end points were summed in the control and exposure groups across these nonoverlapping time intervals. These values were compared when possible to values quoted in the text to ensure accuracy. 16 Eligible studies and extracted data were verified by the senior author (Dr Brown) with any discrepancies resolved by consensus. The internal validity of studies used in this meta-analysis was assessed using the Risk of Bias in Non-Randomized Studies of Interventions tool and the Newcastle-Ottawa scale ( Figure II and Table III in the Data Supplement).
17,18
Clinical End Points
The primary end point of this study was the association between the occurrence of PPMI following TAVR and 30-day all-cause mortality. Secondary end points included 1-year all-cause mortality, neurological events, need for permanent pacing post-TAVR, and post-TAVR aortic regurgitation (AR). Need for permanent pacing post-TAVR was defined as pacing because of worsening cardiac conduction deemed to be directly caused by the index procedure. Studies that reported AR post-TAVR were included if there was transvalvular or paravalvular AR of at least moderate severity. Neurological events were generally defined as any focal neurological deficit persisting for >24 hours (with or without evidence on imaging). Full details of the study-specific definitions can be found in Table II in the Data Supplement.
Statistical Analysis
Data were analyzed using the metan suite of commands in Stata (Stata Corp LP, College Station, TX). Summary estimates are presented as odds ratios (OR) with corresponding 95% CI after random effects modeling. Sensitivity analysis was performed using logarithmic hazard ratios with inverse variance random effects modeling for the primary outcome, as well as exploratory metaregression for the primary outcome with age, left ventricular ejection fraction, Society of Thoracic Surgeons (STS) score, and EuroSCORE as the independent variable. Statistical heterogeneity was quantified with the I 2 statistic. Heterogeneity was quantified as low, moderate, or high based on I 2 values of 25%, 50%, and 75%, respectively. Publication bias was visually assessed by funnel plots and statistically by the Egger test. A 2-sided P value of <0.05 was considered significant.
RESULTS
A total of 249 citations were reviewed and screened with 15 that were deemed potentially eligible for inclusion and subsequently underwent full-text evaluation. Of these, 6 were excluded as data were not reported appropriately or because of inconsistent definitions of PPMI. The full Preferred Reporting Items for Systematic Reviews and Meta-Analyses study flowchart for our search strategy can be seen in Figure 1 . Nine studies comprising 3442 patients met the predefined inclusion criteria and were included in the final analysis. [5] [6] [7] [8] [9] [10] [11] [12] 15 Individual study characteristics, inclusion criteria, and end points are presented in Tables IV and V in the Data  Supplement. Overall, the pooled mean age of the cohort was 81.0±6.6 years, with 51.2% of patients being female. Balloon expandable valves were used in 51.8% patients while self-expanding valves were used in 48.2%. Transfemoral access was used in 82.9%, transapical in 12.7%, trans-subclavian in 1.8%, and transaortic in 2.7% of patients. In total, 876 patients (25.5%) sustained PPMI following TAVR as defined by cardiac biomarker elevation (with or without associated clinical evidence of ischemic insult). The baseline and procedural characteristics stratified by the presence or absence of PPMI are presented in Table 1 and Table VI in the Data Supplement, respectively.
PPMI and Mortality
Nine studies reported data on the association between PPMI and all-cause mortality at 30 days whereas 7 studies reported all-cause mortality at 1 year. The pooled all-cause mortality at 30 days and 1 year was 5.2% and 18.6%, respectively. The occurrence of PPMI during TAVR was associated with a significant increased risk of both 30-day (OR, 4.23; 95% CI, 1.95-9.19; P<0.001) and 1-year (OR, 1.77; 95% CI, 1.05-2.99; P<0.001) mortality. A sensitivity analysis limited to studies using transfemoral-only approach identified 3 studies comprising of 373 patients. With transfemoral-only cases, there remained a significant association between PPMI and 30-day all-cause mortality (OR, 9.2; 95% CI, 3.51-24.07; P<0.001). The corresponding forest plots are shown in Figure 2 , while the clinical event rates for each study are presented in Table 2 . Exploratory metaregression coefficients were not statistically significant for age (P=0.26), left ventricular ejection fraction (P=0.36), STS score (P=0.48), and EuroSCORE (P=0.57), implying they did not demonstrate any influence on the effect estimate.
PPMI and Other Clinical Events
Five studies reported the association between PPMI and the occurrence of neurological events following TAVR with a pooled incidence of 3.4%. PPMI was associated with a significant increased risk of neurological events (OR, 2.72; 95% CI, 1.69-4.37; P<0.001). Four Figure 3 .
Publication Bias
There was no evidence of publication bias by visual funnel plot assessment and through analysis by Egger test (P=0.14; Figure I in the Data Supplement). 
DISCUSSION
The results of these analyses demonstrate that PPMI in the context of TAVR is associated with increased 30-day and 1-year all-cause mortality. We also demonstrate that the occurrence of PPMI was also associated with a greater risk of neurological events and greater likelihood for subsequent permanent pacemaker implantation. These findings suggest that PPMI in the context of TAVR has a potential role in stratifying procedural and patient outcomes. Our analyses demonstrate that patients who sustain a degree of PPMI during TAVR have worse prognosis, for reasons that are likely to be multifactorial. In patients with severe aortic stenosis, the evolution of left ventricular hypertrophy occurs in response to increased afterload. This is met with a cascade of physiological alterations to meet the resultant increase in myocardial oxygen demand, resulting in impaired coronary flow reserve. 19 Any further physiological stress that takes place in these patients puts them at greater likelihood of a mismatch between oxygen demand and supply (type II myocardial infarction), resulting in myocardial necrosis and cardiac enzyme release. Various procedural aspects that take place during TAVR may cause such physiological stress, including periods of hypotension, particularly relating to rapid cardiac pacing, which has been shown to cause a release in highly sensitive troponin. 20 Evidence demonstrates that PPMI occurs more often in TAVR in patients with significant underlying coronary artery disease, 5, 10 which may in part be because of the already impaired coronary flow reserve and thus a greater propensity for intraprocedural type II myocardial infarction. Given the inferior outcomes of patients sustaining PPMI seen in this study, a mechanistic explanation may be offered to a previous pooled analysis, which has demonstrated worsened prognosis for patients undergoing TAVR with a greater residual Synergy Between PCI With Taxus and Cardiac Surgery (SYNTAX) score. 21 Direct instrumentation of myocardium is an additional mechanism for cardiac enzyme release, and this is particularly notable with TAVRs performed via the transapical route. Several studies in this meta-analysis have confirmed a greater proportion of patients sustaining PPMI when performed via this route compared with transfemorally. 5, 7, 12 All patients who underwent TAVR via the transapical approach in one of these studies sustained PPMI, 5 however, a sensitivity analysis performed by the authors found that myocardial injury translated to greater mortality even when excluding transapical access cases. Although caution should be observed because of a widened CI, our sensitivity analysis on studies limited to transfemoral-only approach demonstrated a greater OR for 30-day all-cause mortality. This suggests that cardiac biomarker elevation following TAVR-regardless of cause-may be an indicator of inferior outcomes and is not simply dependent on those patients that sustained PPMI as a consequence of procedural approach.
Ex-vivo models have demonstrated that balloon aortic valvuloplasty can result in embolization of calcified debris to the coronary arteries causing a subsequent rise in cardiac biomarkers. 22 This was corroborated by multifocal patterns of myocardial late enhancement on cardiac magnetic resonance imaging in patients post-TAVR suggesting an embolic cause. 23 Through similar mechanisms, cranial Doppler and magnetic resonance imaging have demonstrated the presence of cerebral embolism during TAVR, 24, 25 which may provide one mechanistic explanation observed for the statistically significant association between the presence of PPMI and neurological events in our results. Alternative explanations have previously been proposed; ≈20% of patients who have acute ischemic strokes have associated serum troponin elevation, potentially by neurally mediated catecholamine release. A large meta-analysis has demonstrated that such patients with troponin elevation in the context of acute ischemic strokes are likely to have worse mortality outcomes. 26 It, therefore, remains unclear if cardiac biomarker elevation is caused by pathophysiological consequences of a neurological event, or if it is an association because of a common underlying cause.
Cardiac magnetic resonance imaging in patients post-TAVR has also demonstrated greater presence of myocardial fibrosis in the left ventricular outflow tract septum, likely because of mechanical stretching during valve implantation which would also promote cardiac biomarker release. 27 Studies have also shown that the occurrence of PPMI is related to the depth of TAVR implant, 9, 28 which in itself is an independent risk factor for atrioventricular node block. 29 This may offer a mechanistic explanation for the association between PPMI and the necessity for post-TAVR cardiac pacing [5] [6] [7] [8] [9] [10] [11] that was seen in this analysis. This could potentially be used to alert clinicians to more closely monitor these patients for bradyarrhythmias postdischarge, perhaps with ambulatory ECG monitoring.
Our analyses suggest that patients incurring PPMI in the context of TAVR are at higher risk for adverse clinical sequelae. Although various mechanistic explanations for PPMI in the context of TAVR have been postulated, it remains unclear whether the associated adverse outcomes are predominantly related to patient baseline characteristics, with therefore PPMI representing a confounding surrogate of greater comorbidity, or whether the biomarker elevation and associated adverse outcomes are largely related to the procedural events. Nevertheless, clinicians should consider the scrupulous provision of clinical care and follow-up for affected patients. As a likely marker for poorer prognosis, further work should be considered to identify the patient-and procedural-specific determinants for PPMI in the context of TAVR. This would not only help further refine the valve device systems and procedural techniques, but it could facilitate delivering care in a more patient-tailored approach. Finally, the relief of aortic stenosis results in regression of left ventricular hypertrophy and reverse myocardial remodeling, which may potentially be augmented by certain drug therapies, such as angiotensin-converting enzyme inhibitors. 30 Given this and the prognostic association of PPMI and left ventricular dysfunction, such targeted pharmacological therapies should be considered in affected patients.
Limitations
Our study has some limitations that should be considered when interpreting results. First, this analysis interrogates the impact of cardiac biomarker elevation alone, and the strength of the association between VARC-2 MI and outcomes remains unknown. Nevertheless, our analysis highlights that the detection of PPMI has important clinical relevance. Second, biomarker thresholds for PPMI were not standardized, with 2 studies using lower thresholds than VARC-2.
6,15 However, the incidence of PPMI in these studies was similar suggesting that the slightly lower threshold did not result in significant over-reporting. Third, neurological events in one of the studies 5 included stroke and transient ischemic attack in contrast to the other studies which only included stroke. Fourth, not all studies excluded patients that had complications requiring open cardiac surgery, and this may have marginally influenced the strength of the association between PPMI and clinical outcomes. However, the incidence of such complications was low (ranging between 0.4% and 1.2%) 5, 12, 15 and, as such, possible inclusion of these patients is unlikely to have had a meaningful impact on our results. This is supported by previous analyses that excluded patients with complications requiring surgery, where the association between PPMI and outcomes was unaffected. 5 Multiple testing correction was also not performed for sensitivity analyses, and therefore, the P values reported need to be interpreted in this context. Finally, we do not have access to patient-level data and have, therefore, been unable to assess the effect of specific patients or procedural characteristics that may influence clinical end points.
